Sangamo Therapeutics Inc (NASDAQ:SGMO) – Investment analysts at Wedbush issued their Q3 2020 earnings per share (EPS) estimates for shares of Sangamo Therapeutics in a report issued on Monday, August 12th. Wedbush analyst L. Moussatos expects that the biopharmaceutical company will post earnings per share of ($0.38) for the quarter. Wedbush has a “Hold” rating and a $11.00 price objective on the stock. Wedbush also issued estimates for Sangamo Therapeutics’ Q4 2020 earnings at ($0.38) EPS.
Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.09. Sangamo Therapeutics had a negative net margin of 136.73% and a negative return on equity of 28.97%. The firm had revenue of $17.55 million during the quarter, compared to analysts’ expectations of $13.58 million. During the same quarter last year, the company posted ($0.17) EPS. The firm’s quarterly revenue was down 18.1% on a year-over-year basis.
Sangamo Therapeutics stock opened at $11.05 on Wednesday. Sangamo Therapeutics has a 52-week low of $6.26 and a 52-week high of $19.25. The firm has a fifty day moving average of $11.58 and a 200-day moving average of $10.55. The firm has a market capitalization of $1.34 billion, a P/E ratio of -15.79 and a beta of 2.93. The company has a quick ratio of 3.98, a current ratio of 3.98 and a debt-to-equity ratio of 0.04.
A number of institutional investors and hedge funds have recently bought and sold shares of SGMO. Wasatch Advisors Inc. boosted its stake in Sangamo Therapeutics by 26.8% during the first quarter. Wasatch Advisors Inc. now owns 6,437,908 shares of the biopharmaceutical company’s stock worth $61,418,000 after buying an additional 1,359,170 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Sangamo Therapeutics by 13.2% in the 2nd quarter. BlackRock Inc. now owns 9,432,178 shares of the biopharmaceutical company’s stock valued at $101,584,000 after purchasing an additional 1,098,030 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Sangamo Therapeutics by 459.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,239,110 shares of the biopharmaceutical company’s stock valued at $14,224,000 after purchasing an additional 1,017,573 shares in the last quarter. Nuveen Asset Management LLC acquired a new stake in shares of Sangamo Therapeutics in the 2nd quarter valued at $8,516,000. Finally, Vanguard Group Inc. boosted its stake in shares of Sangamo Therapeutics by 7.7% in the 2nd quarter. Vanguard Group Inc. now owns 8,309,161 shares of the biopharmaceutical company’s stock valued at $89,490,000 after purchasing an additional 596,573 shares in the last quarter. Hedge funds and other institutional investors own 57.93% of the company’s stock.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.
Featured Article: What Factors Can Affect Return on Equity?
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.